USFDA issues Warning letter to DuPont Nutrition USA Inc., Newark, Delaware facility (FEIĀ FEI 3013947845) for significant deviations in GMP in the manufacture of excipient Avicel. Deviations cited related to Complaints Handling, OOS investigation, Method Validation, Change Management and Data Integrity Read More..
Leave a Comment
You must be logged in to post a comment.